Lichtiger B, Hester J P
Haematologia (Budap). 1986;19(2):81-8.
To study the effects of Rh0D incompatible transfusion of platelets and/or granulocyte concentrates, we analyzed the transfusion history of 118 oncology patients. Patients received a mean 36.2 units of random platelets, a mean 6.2 concentrates of single donor platelets, and a mean 8.4 concentrates of granulocytes. Patients were not treated with anti-Rh0D specific immunoglobulin following the incompatible transfusions. The patients were followed for a mean 9.4 months to detect the appearance of Rh0D antibodies. Of the 118 patients, 3 were lost to follow-up. Of the remaining 115, 2 cases (1.74%) developed anti-Rh0D following administration of the incompatible transfusions.
为研究Rh0D血型不相容的血小板和/或粒细胞浓缩物输血的影响，我们分析了118例肿瘤患者的输血史。患者平均接受了36.2单位的随机血小板、6.2单位的单采血小板浓缩物和8.4单位的粒细胞浓缩物。在进行不相容输血后，患者未接受抗Rh0D特异性免疫球蛋白治疗。对患者进行了平均9.4个月的随访，以检测Rh0D抗体的出现。118例患者中，3例失访。其余115例中，2例（1.74%）在进行不相容输血后产生了抗Rh0D抗体。
